Editorial Open Access
Volume 6 | Issue 1 | DOI: https://doi.org/10.33696/Pharmacol.6.057
Post COVID-19 War Era, Overall Updates and Upgrades Needed to Protect Patients Against Unpredictable Disease’s Progression
Bahram Alamdary Badlou1,*
- 1BBAdvies and Research, Research and Development Dept. Zeist, The Netherlands
Corresponding Author
Bahram Alamdary Badlou, bbadlou@casema.nl
Received Date: August 09, 2024
Accepted Date: August 23, 2024
Badlou BA. Post COVID-19 War Era, Overall Updates and Upgrades Needed to Protect Patients Against Unpredictable Disease’s Progression. Arch Pharmacol Ther. 2024;6(1):50-52.
Copyright: © 2024 Badlou BA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Post COVID-19, Human, Mortality, Morbidity, Management, Health, Diseases, Transmissibility, Humanized mutants, Medicare
Recommended Articles
Identification of the Molecular Basis of Anti-fibrotic Effects of Soluble Guanylate Cyclase Activator Using the Human Lung Fibroblast
Idiopathic pulmonary fibrosis (IPF) is an irreversible fibrotic lung disease with unknown etiology [1-3]. Although two approved medications, pirfenidone and nintedanib, are able to slow down lung function decline in IPF patients, many other chronic pathologic conditions such as dyspnea and pulmonary hypertension (PH) and overall disease progression,
Looking Ahead: Interesting Developments in Menopause Management
There are many exciting developments in the field of midlife women’s health which explain how menopause symptoms, particularly hot flashes, may be an important vital sign and predictor of future health status
The Potential Role of SEPT6 in Liver Fibrosis and Human Hepatocellular Carcinoma
Liver fibrosis is a reversible wound-healing response in which a variety of cells and factors are involved in and results in excessive deposition of extracellular matrix (ECM). Cirrhosis is one of the significant causes of portal hypertension and end-stage liver disease, and it is the 14th most common cause of death around the world. Approximately 1.03 million people worldwide die from liver cirrhosis every year.
The Global Rise of Chronic Diseases: Why Broaden the Paradigm to Include Tick-borne Illness and Environmental Toxin Exposure?
The incidence of chronic diseases is rapidly increasing worldwide. It has been calculated that, in 2001, chronic diseases contributed to approximately 46% of the global burden of disease and 60% of the total reported deaths with that number expected to increase to 57% by 2020, when chronic diseases will account for almost 75% of all deaths worldwide.
Prognostic Role of Human Epididymis Protein 4 (HE4) in Ovarian Cancer Treatment: Our Point of View
In the last 10 years, the marker “Human Epididymis protein 4 (HE4)” for the management of gynecological tumors has entered powerfully in the world literature. At the moment, carrying out an accurate research in the main scientific portals such as PubMed, we can find more than 2,000 works concerning Cancer antigen-125 (Ca125), but those concerning HE4 are less than 400.